Table 3.
Gene set enrichment analysis results using Ingenuity Pathway Analysis (IPA)
| Term | Geneset | # Of genes | p-value(s): UL, LL |
|---|---|---|---|
| Diseases & Disorders | |||
| CNS tumor related | Tissue | 38 | 4.6e−05, 0.006 |
| Serum | 26 | 0.0028, 0.0155 | |
| Cancer | Serum | 36 | 0.0012, 0.0175 |
| Tumor development | Tissue | 36 | 7.6e−05, 0.0012 |
| Meningioma-related | Serum | 5 | 1.47e−04, 0.011 |
| MN-1 related | Tissue | 1 | 0.0135 |
| Molecular and cellular functions | |||
| Immune Response | Serum | 21 | 4.85e−04, 0.0178 |
| Tissue | 1 | 0.00678 | |
| Cell growth/proliferation | Tissue | 19 | 2.32e−04, 0.0284 |
| Serum | 9 | 5.47e−04, 0.0145 | |
| Cellular movement | Tissue | 17 | 5.31e−04, 0.0269 |
| Serum | 14 | 0.0047, 0.0179 | |
| Cell assembly | Tissue | 15 | 1.74e−04, 0.0282 |
| Serum | 5 | 0.0011, 0.0163 | |
| Cell death | Tissue | 15 | 0.0034, 0.0227 |
| Serum | 12 | 0.0011, 0.0145 | |
| Embryonic development | Tissue | 13 | 0.0022, 0.0132 |
| Cell cycle | Serum | 13 | 0.0018, 0.0163 |
| Tissue | 7 | 1.26e−04, 0.0285 | |
| CNS development | Serum | 11 | 0.0017, 0.0018 |
| Cell-to-cell signaling | Tissue | 10 | 0.0017, 0.0269 |
| Serum | 10 | 4.56e−04, 0.0163 | |
| Cell function | Serum | 6 | 0.0018, 0.0181 |
| Cell-mediated immune response | Tissue | 3 | 0.0034, 0.0285 |
| Cell development | Serum | 3 | 0.0012, 0.0018 |
Most relevant disease and biofunctions predicted by Ingenuity Pathway Analysis (IPA) to be regulated by mRNA expression profiles of high-risk hypermitotic meningioma samples (p-values: right-tailed Fisher’s Exact Test).
MN-1 menin-1, mRNA messenger RNA, IPA Ingenuity Pathway Analysis, UL Upper Limit, LL Lower Limit.